U.S. court dismisses Teva case to block copies of Copaxone

A U.S. district court dismissed a case by Teva Pharmaceutical Industries Ltd against the U.S. Food and Drug Administration, part of the Israeli company’s broad legal battle aimed at stopping generic versions of its Copaxone drug for multiple sclerosis. The case, in U.S. District Court in Washington, D.C., was dismissed on Wednesday as being premature because the FDA had not yet approved or rejected the applications for generic forms of the drug, Teva said. \”We are pleased that the judge has requested 24-hour notification of final action from FDA as to the (new drug applications) and continue to evaluate our options,\” Teva spokeswoman Denise Bradley said in a statement.